<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">endoserg</journal-id><journal-title-group><journal-title xml:lang="ru">Эндокринная хирургия</journal-title><trans-title-group xml:lang="en"><trans-title>Endocrine Surgery</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2306-3513</issn><issn pub-type="epub">2310-3965</issn><publisher><publisher-name>Типография «Печатных дел Мастер»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/2306-3513-2007-1-3-11</article-id><article-id custom-type="elpub" pub-id-type="custom">endoserg-3974</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Articles</subject></subj-group></article-categories><title-group><article-title>Феохромоцитома: клинические рекомендации I международного Симпозиума (ISP)</article-title><trans-title-group xml:lang="en"><trans-title>Feokhromotsitoma: klinicheskie rekomendatsii I mezhdunarodnogo Simpoziuma (ISP)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="western" xml:lang="en"><surname>Bel'tsevich</surname><given-names>D G</given-names></name></name-alternatives><email xlink:type="simple">-</email></contrib></contrib-group><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>15</day><month>03</month><year>2007</year></pub-date><volume>1</volume><issue>1</issue><issue-title>№1 (2007)</issue-title><fpage>3</fpage><lpage>11</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Bel'tsevich D.G., 2007</copyright-statement><copyright-year>2007</copyright-year><copyright-holder xml:lang="ru">Bel'tsevich D.G.</copyright-holder><copyright-holder xml:lang="en">Bel'tsevich D.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surg-endojournals.ru/jour/article/view/3974">https://www.surg-endojournals.ru/jour/article/view/3974</self-uri><abstract><p>В рамках I Международного симпозиума по феохромоцитоме (ISP), проведенного в октябре 2005, была обсуждена концепция в отношении катехоламин-продуцирующих опухолей. Были выработаны рекомендации по биохимической и топической диагностике, генетическому обследованию и лечению. В качестве главного диагностического теста и самого точного метода скрининга было рекомендовано определение плазменных или мочевых фракций метанефринов; доверительные интервалы значений метанефринов продемонстрировали наибольшую чувствительность и специфичность. Выбор методов топической диагностики должен основываться на принципе клинической целесообразности. Предоперационная фармакологическая блокада при феохромоцитоме признана обязательной. Генетическое тестирование больных является необходимым в связи с тем, что приблизительно четверть наблюдений феохромоцитом являются результатом герминальных мутаций в пяти вероятных генах; тем не менее этот метод должен применяться по клиническим показаниям, т.к. в настоящее время проверка каждого гена у каждого пациента экономически неэффективна. Показания к конкретному варианту генетического исследования формируются на основании оценки опухолевой локализации, множественности опухолевого поражения, наличию метастазов и типу преобладающей гормональной секреции. Важными проблемами, требующими дальнейшего решения, являются отсутствие адекватных методов дифференциального диагноза злокачественных и доброкачественных опухолей и неудовлетворительные результаты лечения злокачественных опухолей.</p></abstract></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Bravo EL et al. (1979) Circulating and urinarycatecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med 301: 682-686.</mixed-citation><mixed-citation xml:lang="en">Bravo EL et al. (1979) Circulating and urinarycatecholamines in pheochromocytoma. Diagnostic and pathophysiologic implications. N Engl J Med 301: 682-686.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Rosano TG et al. (1991) Advances in catecholamine and metabolite measurements for diagnosis of pheochromocytoma. Clin Chem 37: 1854-1867.</mixed-citation><mixed-citation xml:lang="en">Rosano TG et al. (1991) Advances in catecholamine and metabolite measurements for diagnosis of pheochromocytoma. Clin Chem 37: 1854-1867.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Young WF Jr (1997) Pheochromocytoma: issues in diagnosis &amp; treatment. Compr Ther 23: 319-326.</mixed-citation><mixed-citation xml:lang="en">Young WF Jr (1997) Pheochromocytoma: issues in diagnosis &amp; treatment. Compr Ther 23: 319-326.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Eisenhofer G et al. (2003) Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr Pathol 14: 193-212.</mixed-citation><mixed-citation xml:lang="en">Eisenhofer G et al. (2003) Pheochromocytoma: rediscovery as a catecholamine-metabolizing tumor. Endocr Pathol 14: 193-212.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Gardet V et al. (2001) Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J Hypertens 19: 1029-1035.</mixed-citation><mixed-citation xml:lang="en">Gardet V et al. (2001) Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma. J Hypertens 19: 1029-1035.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Gerlo E and Sevens C (1994) Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocy-toma: diagnostic value in 19 cases. Clin Chem 40: 250-256.</mixed-citation><mixed-citation xml:lang="en">Gerlo E and Sevens C (1994) Urinary and plasma catecholamines and urinary catecholamine metabolites in pheochromocy-toma: diagnostic value in 19 cases. Clin Chem 40: 250-256.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Guller U et al. (2006) Detecting pheochromocytoma: defining the most sensitive test. Ann Surg 243: 102-107.</mixed-citation><mixed-citation xml:lang="en">Guller U et al. (2006) Detecting pheochromocytoma: defining the most sensitive test. Ann Surg 243: 102-107.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Lenders JW et al. (2002) Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287: 1427-1434.</mixed-citation><mixed-citation xml:lang="en">Lenders JW et al. (2002) Biochemical diagnosis of pheochromocytoma: which test is best? JAMA 287: 1427-1434.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Raber W et al. (2000) Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 160: 2957-2963.</mixed-citation><mixed-citation xml:lang="en">Raber W et al. (2000) Diagnostic efficacy of unconjugated plasma metanephrines for the detection of pheochromocytoma. Arch Intern Med 160: 2957-2963.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Sawka AM et al. (2003) A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88: 553558.</mixed-citation><mixed-citation xml:lang="en">Sawka AM et al. (2003) A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines. J Clin Endocrinol Metab 88: 553558.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Unger N et al. (2006) Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 154: 409-417.</mixed-citation><mixed-citation xml:lang="en">Unger N et al. (2006) Diagnostic value of various biochemical parameters for the diagnosis of pheochromocytoma in patients with adrenal mass. Eur J Endocrinol 154: 409-417.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Eisenhofer G et al. (2003) Biochemical diagnosis of pheochromocytoma: how to distinguish truefrom false-positive test results. J Clin Endocrinol Metab 88: 2656-2666.</mixed-citation><mixed-citation xml:lang="en">Eisenhofer G et al. (2003) Biochemical diagnosis of pheochromocytoma: how to distinguish truefrom false-positive test results. J Clin Endocrinol Metab 88: 2656-2666.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Furuta N et al. (1999) Diagnosis of pheochromocytoma using [123I]compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol 6: 119-124.</mixed-citation><mixed-citation xml:lang="en">Furuta N et al. (1999) Diagnosis of pheochromocytoma using [123I]compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol 6: 119-124.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">van der Harst E et al. (2001) [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromo-cytomas. J Clin Endocrinol Metab 86: 685-693.</mixed-citation><mixed-citation xml:lang="en">van der Harst E et al. (2001) [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromo-cytomas. J Clin Endocrinol Metab 86: 685-693.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">O'Riordain DS et al. (1996) Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 20: 916-921.</mixed-citation><mixed-citation xml:lang="en">O'Riordain DS et al. (1996) Clinical spectrum and outcome of functional extraadrenal paraganglioma. World J Surg 20: 916-921.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hoegerle S et al. (2002) Pheochromocytomas: detection with 18F DOPA whole body PET-initial results. Radiology 222: 507-512.</mixed-citation><mixed-citation xml:lang="en">Hoegerle S et al. (2002) Pheochromocytomas: detection with 18F DOPA whole body PET-initial results. Radiology 222: 507-512.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Ilias I et al. (2002) 6-[18F]-fluorodopamine positron emission tomography versus [131I] metaiodobenzylguanidine scintigraphy in the evaluation of patients with pheochromocytoma. Abstract P3-511. Presented at the 84th Annual Meeting of the Endocrine Society: 2002 June 19-22; San Fransisco, CA.</mixed-citation><mixed-citation xml:lang="en">Ilias I et al. (2002) 6-[18F]-fluorodopamine positron emission tomography versus [131I] metaiodobenzylguanidine scintigraphy in the evaluation of patients with pheochromocytoma. Abstract P3-511. Presented at the 84th Annual Meeting of the Endocrine Society: 2002 June 19-22; San Fransisco, CA.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Mann GN et al. (2006) [(11)C]metahydroxyephedrine and [(18)f]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol 13: 187-197.</mixed-citation><mixed-citation xml:lang="en">Mann GN et al. (2006) [(11)C]metahydroxyephedrine and [(18)f]fluorodeoxyglucose positron emission tomography improve clinical decision making in suspected pheochromocytoma. Ann Surg Oncol 13: 187-197.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Pacak K et al. (2001) 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38: 6-8.</mixed-citation><mixed-citation xml:lang="en">Pacak K et al. (2001) 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38: 6-8.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Shulkin B et al. (1992) PET scanning with hydroxyephedrine: A new approach to the localization of pheochromocytoma. J Nucl Med 33: 1125-1131.</mixed-citation><mixed-citation xml:lang="en">Shulkin B et al. (1992) PET scanning with hydroxyephedrine: A new approach to the localization of pheochromocytoma. J Nucl Med 33: 1125-1131.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Trampal C et al. (2004) Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology 230: 423-428.</mixed-citation><mixed-citation xml:lang="en">Trampal C et al. (2004) Pheochromocytomas: detection with 11C hydroxyephedrine PET. Radiology 230: 423-428.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Shulkin BL et al. (1999) Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-D-glucose PET. Nucl Med 212: 35-41.</mixed-citation><mixed-citation xml:lang="en">Shulkin BL et al. (1999) Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-D-glucose PET. Nucl Med 212: 35-41.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Ilias I and Pacak K (2004) Current approaches and recommended algorithm for the diagnostic localization of pheochromocy-toma. J Clin Endocrinol Metab 89: 479-491.</mixed-citation><mixed-citation xml:lang="en">Ilias I and Pacak K (2004) Current approaches and recommended algorithm for the diagnostic localization of pheochromocy-toma. J Clin Endocrinol Metab 89: 479-491.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Mamede M et al. (2006) Discordant localization of 2-[18F]-flu-oro-2-deoxy-D-glucose in 6-[18F]fluorodopamineand [123I]-metaiodobenzylguanidinenegative metastatic pheochromocytoma sites. Nucl Med Commun 27: 31-36.</mixed-citation><mixed-citation xml:lang="en">Mamede M et al. (2006) Discordant localization of 2-[18F]-flu-oro-2-deoxy-D-glucose in 6-[18F]fluorodopamineand [123I]-metaiodobenzylguanidinenegative metastatic pheochromocytoma sites. Nucl Med Commun 27: 31-36.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Astuti D et al. (2001) Germline SDHD mutation in familial phaeochromocytoma. Lancet 357: 1181-1182.</mixed-citation><mixed-citation xml:lang="en">Astuti D et al. (2001) Germline SDHD mutation in familial phaeochromocytoma. Lancet 357: 1181-1182.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Astuti D et al. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromo-cytoma and to familial paraganglioma. Am J Hum Genet 69: 49-54.</mixed-citation><mixed-citation xml:lang="en">Astuti D et al. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromo-cytoma and to familial paraganglioma. Am J Hum Genet 69: 49-54.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Baysal BE et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287: 848-851.</mixed-citation><mixed-citation xml:lang="en">Baysal BE et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287: 848-851.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Baysal BE et al. (2002) Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 39: 178-183.</mixed-citation><mixed-citation xml:lang="en">Baysal BE et al. (2002) Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas. J Med Genet 39: 178-183.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Gimenez-Roqueplo AP et al. (2003) Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochro-mocytomas. Cancer Res 63: 5615-5621.</mixed-citation><mixed-citation xml:lang="en">Gimenez-Roqueplo AP et al. (2003) Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochro-mocytomas. Cancer Res 63: 5615-5621.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Maher ER et al. (1991) Von Hippel-Lindau disease: a genetic study. J Med Genet 28: 443-447.</mixed-citation><mixed-citation xml:lang="en">Maher ER et al. (1991) Von Hippel-Lindau disease: a genetic study. J Med Genet 28: 443-447.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Neumann HPH et al. (2002) Germ-line mutations in nonsyn-dromic pheochromocytoma. New Engl J Med 346: 1459-1466.</mixed-citation><mixed-citation xml:lang="en">Neumann HPH et al. (2002) Germ-line mutations in nonsyn-dromic pheochromocytoma. New Engl J Med 346: 1459-1466.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Bryant J et al. (2003) Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 95: 1196-1204.</mixed-citation><mixed-citation xml:lang="en">Bryant J et al. (2003) Pheochromocytoma: the expanding genetic differential diagnosis. J Natl Cancer Inst 95: 1196-1204.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Gagel RF et al. (1988) The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 318: 478-484.</mixed-citation><mixed-citation xml:lang="en">Gagel RF et al. (1988) The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 318: 478-484.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Mulligan LM et al. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363: 458-460.</mixed-citation><mixed-citation xml:lang="en">Mulligan LM et al. (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363: 458-460.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Zeiger MA et al. (1995) Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von Hippel-Lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes Cancer 13: 151-156.</mixed-citation><mixed-citation xml:lang="en">Zeiger MA et al. (1995) Loss of heterozygosity on the short arm of chromosome 3 in sporadic, von Hippel-Lindau disease-associated, and familial pheochromocytoma. Genes Chromosomes Cancer 13: 151-156.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Jimenez C et al. (2006) Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 91: 2851-2858.</mixed-citation><mixed-citation xml:lang="en">Jimenez C et al. (2006) Should patients with apparently sporadic pheochromocytomas or paragangliomas be screened for hereditary syndromes? J Clin Endocrinol Metab 91: 2851-2858.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Elder EE et al. (2005) Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. J Surg Oncol 89: 193-201.</mixed-citation><mixed-citation xml:lang="en">Elder EE et al. (2005) Pheochromocytoma and functional paraganglioma syndrome: no longer the 10% tumor. J Surg Oncol 89: 193-201.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Lenders JW et al. (2005) Phaeochromocytoma. Lancet 366: 665-675.</mixed-citation><mixed-citation xml:lang="en">Lenders JW et al. (2005) Phaeochromocytoma. Lancet 366: 665-675.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Neumann HP et al. (2002) Germ-line mutations in nonsyn-dromic pheochromocytoma. N Engl J Med 346: 1459-1466.</mixed-citation><mixed-citation xml:lang="en">Neumann HP et al. (2002) Germ-line mutations in nonsyn-dromic pheochromocytoma. N Engl J Med 346: 1459-1466.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Amar L et al. (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23: 8812-8818.</mixed-citation><mixed-citation xml:lang="en">Amar L et al. (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23: 8812-8818.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Benn DE et al. (2005) Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91: 790-792.</mixed-citation><mixed-citation xml:lang="en">Benn DE et al. (2005) Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91: 790-792.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Barontini M et al. (2006) Characteristics of pheochromocy-toma in a 4to 20-year-old population. Ann NY Acad Sci 1073: 30-37.</mixed-citation><mixed-citation xml:lang="en">Barontini M et al. (2006) Characteristics of pheochromocy-toma in a 4to 20-year-old population. Ann NY Acad Sci 1073: 30-37.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Weinhausel A et al. (2003) Long-term follow up of a "sporadic" unilateral pheochromocytoma revealing multiple endocrine neoplasia MEN2A-2 in an elderly woman. Endocr Pathol 14: 375-382.</mixed-citation><mixed-citation xml:lang="en">Weinhausel A et al. (2003) Long-term follow up of a "sporadic" unilateral pheochromocytoma revealing multiple endocrine neoplasia MEN2A-2 in an elderly woman. Endocr Pathol 14: 375-382.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Astuti D et al. (2003) Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clin Endocrinol (Oxf) 59: 728-733.</mixed-citation><mixed-citation xml:lang="en">Astuti D et al. (2003) Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility. Clin Endocrinol (Oxf) 59: 728-733.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Eisenhofer G et al. (1999) Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340: 1872-1879.</mixed-citation><mixed-citation xml:lang="en">Eisenhofer G et al. (1999) Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340: 1872-1879.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Bravo EL and Tagle R (2003) Pheochromocytoma: stateof-the-art and future prospects. Endocr Rev 24: 539-553.</mixed-citation><mixed-citation xml:lang="en">Bravo EL and Tagle R (2003) Pheochromocytoma: stateof-the-art and future prospects. Endocr Rev 24: 539-553.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Kinney MA et al. (2002) Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 16: 359-369.</mixed-citation><mixed-citation xml:lang="en">Kinney MA et al. (2002) Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 16: 359-369.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Pacak K et al. (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134: 315-329.</mixed-citation><mixed-citation xml:lang="en">Pacak K et al. (2001) Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med 134: 315-329.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Prys-Roberts C (2000) Phaeochromocytoma-recent progress in its management. Br J Anaesth 85: 44-57.</mixed-citation><mixed-citation xml:lang="en">Prys-Roberts C (2000) Phaeochromocytoma-recent progress in its management. Br J Anaesth 85: 44-57.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Proye C et al. (1989) Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients. Surgery 106: 1149-1154.</mixed-citation><mixed-citation xml:lang="en">Proye C et al. (1989) Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients. Surgery 106: 1149-1154.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Plouin PF et al. (1997) Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 29: 1133-1139.</mixed-citation><mixed-citation xml:lang="en">Plouin PF et al. (1997) Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 29: 1133-1139.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Janetschek G et al. (1998) Laparoscopic surgery for pheochro-mocytoma: adrenalectomy, partial resection, excision of paragangliomas. J Urol 160: 330-334.</mixed-citation><mixed-citation xml:lang="en">Janetschek G et al. (1998) Laparoscopic surgery for pheochro-mocytoma: adrenalectomy, partial resection, excision of paragangliomas. J Urol 160: 330-334.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Brunt LM et al. (2002) Adrenalectomy for familial pheochro-mocytoma in the laparoscopic era. Ann Surg 235: 713-720.</mixed-citation><mixed-citation xml:lang="en">Brunt LM et al. (2002) Adrenalectomy for familial pheochro-mocytoma in the laparoscopic era. Ann Surg 235: 713-720.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Lee J et al. (1996) Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 120: 1064-1070.</mixed-citation><mixed-citation xml:lang="en">Lee J et al. (1996) Cortical-sparing adrenalectomy for patients with bilateral pheochromocytoma. Surgery 120: 1064-1070.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Nambirajan T et al. (2005) Laparoscopic adrenal surgery for recurrent tumours in patients with hereditary phaeochromocytoma. Eur Urol 47: 622-626.</mixed-citation><mixed-citation xml:lang="en">Nambirajan T et al. (2005) Laparoscopic adrenal surgery for recurrent tumours in patients with hereditary phaeochromocytoma. Eur Urol 47: 622-626.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Yip L et al. (2004) Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198: 525-534.</mixed-citation><mixed-citation xml:lang="en">Yip L et al. (2004) Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198: 525-534.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Koch CA et al. (2002) Pheochromocytoma in von Hippel-Lindau disease: Distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol 13: 17-27.</mixed-citation><mixed-citation xml:lang="en">Koch CA et al. (2002) Pheochromocytoma in von Hippel-Lindau disease: Distinct histopathologic phenotype compared to pheochromocytoma in multiple endocrine neoplasia type 2. Endocr Pathol 13: 17-27.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">DeLellis RA et al. (Eds; 2004) Tumours of Endocrine Organs. Lyon: IARC Press.</mixed-citation><mixed-citation xml:lang="en">DeLellis RA et al. (Eds; 2004) Tumours of Endocrine Organs. Lyon: IARC Press.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Kimura N et al. (2005) Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16: 23-32.</mixed-citation><mixed-citation xml:lang="en">Kimura N et al. (2005) Histological grading of adrenal and extra-adrenal pheochromocytomas and relationship to prognosis: a clinicopathological analysis of 116 adrenal pheochromocytomas and 30 extra-adrenal sympathetic paragangliomas including 38 malignant tumors. Endocr Pathol 16: 23-32.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Linnoila RI et al. (1990) Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21: 11681180.</mixed-citation><mixed-citation xml:lang="en">Linnoila RI et al. (1990) Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21: 11681180.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson LD (2002) Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26: 551-566.</mixed-citation><mixed-citation xml:lang="en">Thompson LD (2002) Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26: 551-566.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Lack EE et al. (2003) Recommendations for the reporting of extra-adrenal paragangliomas. The Association of Directors of Anatomic and Surgical Pathology. Hum Pathol 34: 112-113.</mixed-citation><mixed-citation xml:lang="en">Lack EE et al. (2003) Recommendations for the reporting of extra-adrenal paragangliomas. The Association of Directors of Anatomic and Surgical Pathology. Hum Pathol 34: 112-113.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Association of Directors of Anatomic and Surgical Pathology [http://www.adasp.org] (accessed 15 September 2006).</mixed-citation><mixed-citation xml:lang="en">Association of Directors of Anatomic and Surgical Pathology [http://www.adasp.org] (accessed 15 September 2006).</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Lack EE (1999) Recommendations for the reporting of tumors of the adrenal cortex and medulla. Association of Directors of Anatomic and Surgical Pathology. Virchows Arch 435: 87-91.</mixed-citation><mixed-citation xml:lang="en">Lack EE (1999) Recommendations for the reporting of tumors of the adrenal cortex and medulla. Association of Directors of Anatomic and Surgical Pathology. Virchows Arch 435: 87-91.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">The Royal College of Pathologists [http://www.rcpath.org] (accessed 15 September 2006)</mixed-citation><mixed-citation xml:lang="en">The Royal College of Pathologists [http://www.rcpath.org] (accessed 15 September 2006)</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Eisenhofer G et al. (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11: 423-436.</mixed-citation><mixed-citation xml:lang="en">Eisenhofer G et al. (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11: 423-436.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">August C et al. (2004) CGH and CD 44/MIB-1 immunohisto-chemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod Pathol 17: 1119-1128.</mixed-citation><mixed-citation xml:lang="en">August C et al. (2004) CGH and CD 44/MIB-1 immunohisto-chemistry are helpful to distinguish metastasized from nonmetastasized sporadic pheochromocytomas. Mod Pathol 17: 1119-1128.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Goldstein RE et al. (1999) Clinical experience over 48 years with pheochromocytoma. Ann Surg 229: 755-764.</mixed-citation><mixed-citation xml:lang="en">Goldstein RE et al. (1999) Clinical experience over 48 years with pheochromocytoma. Ann Surg 229: 755-764.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">John H et al. (1999) Pheochromocytomas: can malignant potential be predicted? Urology 53: 679-683.</mixed-citation><mixed-citation xml:lang="en">John H et al. (1999) Pheochromocytomas: can malignant potential be predicted? Urology 53: 679-683.</mixed-citation></citation-alternatives></ref><ref id="cit70"><label>70</label><citation-alternatives><mixed-citation xml:lang="ru">Proye CA et al. (1994) -The» pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? World J Surg 18: 467-472.</mixed-citation><mixed-citation xml:lang="en">Proye CA et al. (1994) -The» pheochromocytoma: a benign, intra-adrenal, hypertensive, sporadic unilateral tumor. Does it exist? World J Surg 18: 467-472.</mixed-citation></citation-alternatives></ref><ref id="cit71"><label>71</label><citation-alternatives><mixed-citation xml:lang="ru">Whalen RK et al. (1992) Extra-adrenal pheochromocytoma. J Urol 147: 1-10.</mixed-citation><mixed-citation xml:lang="en">Whalen RK et al. (1992) Extra-adrenal pheochromocytoma. J Urol 147: 1-10.</mixed-citation></citation-alternatives></ref><ref id="cit72"><label>72</label><citation-alternatives><mixed-citation xml:lang="ru">Mundschenk J and Lehnert H (1998) Malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 106: 373-376.</mixed-citation><mixed-citation xml:lang="en">Mundschenk J and Lehnert H (1998) Malignant pheochromocytoma. Exp Clin Endocrinol Diabetes 106: 373-376.</mixed-citation></citation-alternatives></ref><ref id="cit73"><label>73</label><citation-alternatives><mixed-citation xml:lang="ru">Brouwers FM et al. (2005) Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr Relat Cancer 12: 263-272.</mixed-citation><mixed-citation xml:lang="en">Brouwers FM et al. (2005) Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr Relat Cancer 12: 263-272.</mixed-citation></citation-alternatives></ref><ref id="cit74"><label>74</label><citation-alternatives><mixed-citation xml:lang="ru">Averbuch SD et al. (1988) Malignant pheochromocy-toma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109: 267-273.</mixed-citation><mixed-citation xml:lang="en">Averbuch SD et al. (1988) Malignant pheochromocy-toma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med 109: 267-273.</mixed-citation></citation-alternatives></ref><ref id="cit75"><label>75</label><citation-alternatives><mixed-citation xml:lang="ru">Rose B et al. (2003) High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98: 239-248.</mixed-citation><mixed-citation xml:lang="en">Rose B et al. (2003) High-dose 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98: 239-248.</mixed-citation></citation-alternatives></ref><ref id="cit76"><label>76</label><citation-alternatives><mixed-citation xml:lang="ru">Safford SD et al. (2003) Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134: 956-962.</mixed-citation><mixed-citation xml:lang="en">Safford SD et al. (2003) Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134: 956-962.</mixed-citation></citation-alternatives></ref><ref id="cit77"><label>77</label><citation-alternatives><mixed-citation xml:lang="ru">Takahashi K et al. (1999) Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. Intern Med 38: 349-354.</mixed-citation><mixed-citation xml:lang="en">Takahashi K et al. (1999) Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization. Intern Med 38: 349-354.</mixed-citation></citation-alternatives></ref><ref id="cit78"><label>78</label><citation-alternatives><mixed-citation xml:lang="ru">Loh KC et al. (1997) The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 20: 648-658.</mixed-citation><mixed-citation xml:lang="en">Loh KC et al. (1997) The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 20: 648-658.</mixed-citation></citation-alternatives></ref><ref id="cit79"><label>79</label><citation-alternatives><mixed-citation xml:lang="ru">Mukherjee JJ et al. (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf) 55: 47-60.</mixed-citation><mixed-citation xml:lang="en">Mukherjee JJ et al. (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG]. Clin Endocrinol (Oxf) 55: 47-60.</mixed-citation></citation-alternatives></ref><ref id="cit80"><label>80</label><citation-alternatives><mixed-citation xml:lang="ru">Chan EC and Ho PC (2000) High-performance liquid chromatography/atmospheric pressure chemical ionization mass spectro-metric method for the analysis of catecholamines and metanephrines in human urine. Rapid Commun Mass Spectrom 14: 1959-1964.</mixed-citation><mixed-citation xml:lang="en">Chan EC and Ho PC (2000) High-performance liquid chromatography/atmospheric pressure chemical ionization mass spectro-metric method for the analysis of catecholamines and metanephrines in human urine. Rapid Commun Mass Spectrom 14: 1959-1964.</mixed-citation></citation-alternatives></ref><ref id="cit81"><label>81</label><citation-alternatives><mixed-citation xml:lang="ru">Crockett DK et al. (2002) Rapid analysis of metanephrine and normetanephrine in urine by gas chromatography-mass spectrometry. Clin Chem 48: 332-337.</mixed-citation><mixed-citation xml:lang="en">Crockett DK et al. (2002) Rapid analysis of metanephrine and normetanephrine in urine by gas chromatography-mass spectrometry. Clin Chem 48: 332-337.</mixed-citation></citation-alternatives></ref><ref id="cit82"><label>82</label><citation-alternatives><mixed-citation xml:lang="ru">Lagerstedt SA et al. (2004) Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma. Clin Chem 50: 603-611.</mixed-citation><mixed-citation xml:lang="en">Lagerstedt SA et al. (2004) Measurement of plasma free metanephrine and normetanephrine by liquid chromatography-tandem mass spectrometry for diagnosis of pheochromocytoma. Clin Chem 50: 603-611.</mixed-citation></citation-alternatives></ref><ref id="cit83"><label>83</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor RL and Singh RJ (2002) Validation of liquid chro-matography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. Clin Chem 48: 533-539.</mixed-citation><mixed-citation xml:lang="en">Taylor RL and Singh RJ (2002) Validation of liquid chro-matography-tandem mass spectrometry method for analysis of urinary conjugated metanephrine and normetanephrine for screening of pheochromocytoma. Clin Chem 48: 533-539.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
